Future calibrated fMRI studies, in which the latter challenges are overcome, may provide new insights into the pathophysiology of AD that go beyond hyperphosphorylated tau pathology, amyloid deposition and glucose uptake. The gene discussed is MAPT; the disease is Alzheimer disease.